Oncolytics Biotech issued new U.S. patent

NewsGuard 100/100 Score
Aug 8 2007

Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,252,817 entitled "Viruses for the Treatment of Cellular Proliferative Disorders."

The claims cover the use of modified herpes simplex viruses (HSV) to treat cellular proliferative disorders which include neoplasias (cancers). "This patent expands our intellectual property portfolio in viruses other than reovirus," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.

http://www.oncolyticsbiotech.com/

Posted in: Medical Patent News

Tags: ,

Comments (0)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback